The estimated Net Worth of Stephen Christopher Linthwaite is at least $5.49 Millón dollars as of 22 February 2022. Mr. Linthwaite owns over 22,417 units of Standard BioTools Inc stock worth over $1,264,880 and over the last 8 years he sold FLDM stock worth over $514,009. In addition, he makes $3,713,060 as President, Chief Executive Officer y Director at Standard BioTools Inc.
Stephen has made over 24 trades of the Standard BioTools Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 22,417 units of FLDM stock worth $83,167 on 22 February 2022.
The largest trade he's ever made was exercising 177,417 units of Standard BioTools Inc stock on 20 May 2021 worth over $658,217. On average, Stephen trades about 19,915 units every 53 days since 2016. As of 22 February 2022 he still owns at least 340,938 units of Standard BioTools Inc stock.
You can see the complete history of Mr. Linthwaite stock trades at the bottom of the page.
Stephen Christopher Linthwaite serves as President, Chief Executive Officer, Director of the Company. From August 2003 to April 2016, Mr. Linthwaite held various managerial positions at Thermo Fisher Scientific Inc., a life sciences company, and prior to its acquisition by Thermo Fisher, at Life Technologies Corporation, a life sciences company, including president, genetic sciences division, from December 2014 to April 2016, president, genetic analysis platform, from September 2011 to December 2014, and various other managerial positions at Invitrogen prior to the creation of Life Technologies through a merger of Invitrogen and Applied Biosystems. Prior to joining Invitrogen, Mr. Linthwaite held various strategic consulting roles. Mr. Linthwaite served on the board of directors of Claritas Genomics, Inc. from December 2014 to April 2016. Mr. Linthwaite received an M.B.A. from the University of Virginia (Darden) School of Business, and a B.A. in Foreign Affairs from the University of Virginia. Prior to business school, Mr. Linthwaite served on active duty in the U.S. Army as an armor officer.
As the President, Chief Executive Officer y Director of Standard BioTools Inc, the total compensation of Stephen Linthwaite at Standard BioTools Inc is $3,713,060. There are no executives at Standard BioTools Inc getting paid more.
Stephen Linthwaite is 48, he's been the President, Chief Executive Officer y Director of Standard BioTools Inc since 2016. There are 8 older and 4 younger executives at Standard BioTools Inc. The oldest executive at Standard BioTools Inc is Vikram Jog, 65, who is the Chief Financial Officer.
Stephen's mailing address filed with the SEC is C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, STE 2000, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 14 years, insiders at Standard BioTools Inc have traded over $29,087,682 worth of Standard BioTools Inc stock and bought 4,143,303 units worth $24,269,186 . The most active insiders traders include Easterly Partners Llcle Par..., Capital Strategies, L.P.Lev... y Samuel D Colella. On average, Standard BioTools Inc executives and independent directors trade stock every 9 days with the average trade being worth of $72,208. The most recent stock trade was executed by Nicolas Barthelemy on 1 April 2022, trading 20,993 units of FLDM stock currently worth $78,514.
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, the Company strives to increase the quality of life for all.
Standard BioTools Inc executives and other stock owners filed with the SEC include: